

## Precirix and IFE sign clinical trial manufacturing agreement

**Brussels, Belgium and Kjeller, Norway, 13 September 2021** – Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and the Institute for Energy Technology (IFE), a manufacturer of radiopharmaceutical products based in Norway, today announced an agreement for the supply of Precirix' radiopharmaceuticals in Europe. The agreement with IFE will provide long-term clinical trial supply of Precirix' product candidates that combine camelid-derived single-domain antibodies with Iodine-131. Technology transfer and manufacturing setup will commence in the following weeks.

*“Securing clinical supply is of significant importance to execute our ambitious clinical development plans. Precirix is currently running a Phase I/II trial and advancing its second pipeline product to the clinic.”, said Ruth Devenyns, Chief Executive Officer of Precirix, “We are excited to start working with IFE, a leader in the field of radiopharmaceutical manufacturing. With this third supplier on board, we will be able to cover North-America as well as Europe, the major regions targeted in our clinical trials.”*

Erik Flatmark, Director Radiopharmacy division at IFE commented, *“Precirix' platform of iodinated sdAbs is proving to be a solid platform technology. We look forward to working with the company and contribute to bringing these innovative radiopharmaceuticals to patients.”*

### **About Precirix NV**

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix' technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment.

# PRECIRIX

# IFE

PRESS RELEASE  
13 September 2021

## About IFE

The Institute for energy technology (IFE) was founded by the Norwegian Government in 1948 to develop Norway's nuclear research. Norway was a pioneer in nuclear research and was the sixth country in the world to build a nuclear reactor in 1951.

Today IFE is an independent foundation located in Kjeller and in Halden. The institute has both Norwegian and international customers and has a turnover of around NOK 1 billion a year. IFE is one of Norway's largest research institutes with around 600 employees. IFE has leading research environments within renewable energy, digital systems, nuclear technology, radiopharmaceuticals, and industrial development.

## For further information, please contact:

Precirix NV  
Ruth Devenyns, CEO Precirix  
+32 2 479 93 60  
[info@precirix.com](mailto:info@precirix.com)  
[www.precirix.com](http://www.precirix.com)

IFE  
Silje Aspholm Hole  
Sector Director / Communications Director  
[silje.aspholm.hole@ife.no](mailto:silje.aspholm.hole@ife.no)  
[www.ife.no](http://www.ife.no)